ALNY News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AL

Mkt Cap

$32.69B

Volume

933.86K

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory BoardAerska, a biotechnology company developing RNA medicines for CNS diseases through its antibody-oligonucleotide conjugate (AOC) platform, has appointed Laura Sepp-Lorenzino to its Scientific Advisory Board. Sepp-Lorenzino brings over 30 years of experience in genetic medicines and nucleic acid therapies, previously serving as Chief Scientific Officer at Intellia Therapeutics and leading nucleic acid programs at Vertex Pharmaceuticals.GlobeNewswire Inc. · Sep 17, 2026

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta TherapeuticsThe global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.GlobeNewswire Inc. · Sep 15, 2026

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?TG Therapeutics shares have gained 15.1% since its last earnings report in early September 2026. While the company beat revenue expectations with $240.3M (up 70.3% YoY) driven by strong Briumvi sales, it missed EPS estimates at $0.05 vs. $0.41 expected. The company raised its 2026 revenue guidance to ~$950M. However, analyst estimates have trended downward since the report, and the stock received a Zacks Rank #3 (Hold) with poor Growth and Momentum scores, suggesting limited upside ahead.Zacks Investment Research · Sep 2, 2026

ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the FirmLaw firm Bragar Eagel & Squire is investigating Alnylam Pharmaceuticals for potential federal securities law violations following the company's July 30, 2026 announcement of a $200 million reduction in TTR product sales guidance. The guidance cut, attributed to normalization of growth after initial market launch, triggered a 28.35% intraday stock price decline. The firm is seeking stockholders who suffered losses to participate in potential litigation.GlobeNewswire Inc. · Aug 4, 2026

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzThe Law Offices of Frank R. Cruz is investigating Alnylam Pharmaceuticals for possible federal securities law violations. On July 30, 2026, Alnylam lowered its TTR product sales guidance by approximately $200 million due to slower-than-expected growth in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a 28.35% intraday stock decline, causing investor losses.GlobeNewswire Inc. · Aug 3, 2026

ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudLaw firm Kirby McInerney LLP is investigating potential securities fraud claims against Alnylam Pharmaceuticals following the company's announcement on July 30, 2026, that it lowered TTR product sales guidance by approximately $200 million due to normalization of growth in the ATTR-CM market after satisfying pent-up demand. The stock fell 28% ($81.14 per share) to $205.48 on the news.GlobeNewswire Inc. · Jul 31, 2026

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200Atlas Healthcare Fund, managed by VST Capital, showcased its track record of early conviction investments in healthcare, with notable positions in Eli Lilly (entered at $350, now trading above $1,200), Alnylam Pharmaceuticals, TransMedics Group, and Inari Medical. The fund has delivered cumulative net returns of +1,720.9% since inception in January 2020, averaging over 57% annually, by identifying clinically differentiated technologies before mainstream market recognition.GlobeNewswire Inc. · Jul 17, 2026

Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines ExpandThe global oligonucleotide contract development and manufacturing organization (CDMO) market is experiencing strong growth driven by expanding RNA-targeted medicine pipelines, increased outsourcing of complex synthesis and manufacturing, and rising demand for precision medicine. The market is projected to grow at a 21.81% CAGR through 2031, with contract manufacturing leading at 51.68% market share in 2025. Antisense oligonucleotides dominate at 58.23% revenue, while siRNA is the fastest-growing segment at 23.25% CAGR. Asia-Pacific is the fastest-growing region at 24.56% CAGR, driven by capacity expansion in China, South Korea, and Japan.GlobeNewswire Inc. · Jul 15, 2026

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS InsiderThe transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.GlobeNewswire Inc. · Jul 7, 2026

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.Alnylam Pharmaceuticals has gained strong analyst support with 21 of 29 analysts rating it as buy or strong buy, with an average price target of $436 (45% upside). The company is transitioning from a clinical biotech to a profitable commercial powerhouse, with Q1 product revenue surging 121% year-over-year to $1.04 billion, driven by its ATTR franchise. The company's pipeline is expanding into mainstream markets like cardiomyopathy and hypertension, supported by a unique RNAi delivery platform that creates a competitive moat. However, the stock trades at a high valuation of 75x trailing earnings, with risks from competitive pricing pressure.The Motley Fool · Jul 2, 2026

AL

ALNYAlnylam Pharmaceuticals, Inc.

ALNY

Pay with—

Available Balance0.00

Your PositionYou don't own any ALNY yet.

Related Tickers

Earnings